The role of pharmaceutical agents in hearing loss management and prevention

In the future, possibly within 5 or earlier, we may be able to prevent or reduce permanent noise- and drug-induced hearing loss by pharmacologic otoprotective agents. Research suggests these agents may be given before or in some cases even after drug or noise exposure. This presentation will review current research in otoprotective agents for drug- and noise- induced ototoxicity including Dr. Campbell's own research with D-methionine as an otoprotective agent. This presentation will emphasize oral agents in or approaching FDA approved clinical trials. These agents could change audiologic and otolaryngologic practice. These agents are currently in or approaching clinical trials to prevent cisplatin-induced, aminoglycoside induced and noise induced hearing loss. Dr. Campbell's own clinical trials with D-methionine, funded by the US Department of Defense and under FDA IND approval, are currently in a Phase 3 clinical trial at Ft. Jackson to prevent noise induced hearing loss and tinnitus at Ft. Jackson. This clinical trial and Dr. Campbell's research was featured on the front page of the Wall Street Journal in 2015. Further some otoprotective agents for cisplatin induced hearing loss have the potential to reduce other side effects of cancer treatments.

Biography

Kathleen Campbell, PhD is a Distinguished Scholar and Professor at Southern Illinois University (SIU) School of Medicine. She served on the American Academy of Audiology Board of Directors, received an American Academy of Audiology Presidential Citation for her work in developing professional practice standards for the American Academy of Audiology, American Speech Language and Hearing Association and the Department of Veteran’s affairs. She also received two medical innovators awards and is a fellow of the American Speech Language and Hearing Association. She authored Essential Audiology for Physicians and edited/authored Pharmacology and Ototoxicity for Audiologists. She has received over 60 grants from National Institutes of Health, US Department of Defense and other agencies for her research in otoprotective agents and is the sole inventor for the protective agent D-methionine patents.

Notes:

Kathleen Campbell
Southern Illinois University, USA

The role of pharmaceutical agents in hearing loss management and prevention

In the future, possibly within 5 or earlier, we may be able to prevent or reduce permanent noise- and drug-induced hearing loss by pharmacologic otoprotective agents. Research suggests these agents may be given before or in some cases even after drug or noise exposure. This presentation will review current research in otoprotective agents for drug- and noise- induced ototoxicity including Dr. Campbell’s own research with D-methionine as an otoprotective agent. This presentation will emphasize oral agents in or approaching FDA approved clinical trials. These agents could change audiologic and otolaryngologic practice. These agents are currently in or approaching clinical trials to prevent cisplatin-induced, aminoglycoside induced and noise induced hearing loss. Dr. Campbell’s own clinical trials with D-methionine, funded by the US Department of Defense and under FDA IND approval, are currently in a Phase 3 clinical trial at Ft. Jackson to prevent noise induced hearing loss and tinnitus at Ft. Jackson. This clinical trial and Dr. Campbell’s research was featured on the front page of the Wall Street Journal in 2015. Further some otoprotective agents for cisplatin induced hearing loss have the potential to reduce other side effects of cancer treatments.

Biography

Kathleen Campbell, PhD is a Distinguished Scholar and Professor at Southern Illinois University (SIU) School of Medicine. She served on the American Academy of Audiology Board of Directors, received an American Academy of Audiology Presidential Citation for her work in developing professional practice standards for the American Academy of Audiology, American Speech Language and Hearing Association and the Department of Veteran’s affairs. She also received two medical innovators awards and is a fellow of the American Speech Language and Hearing Association. She authored Essential Audiology for Physicians and edited/authored Pharmacology and Ototoxicity for Audiologists. She has received over 60 grants from National Institutes of Health, US Department of Defense and other agencies for her research in otoprotective agents and is the sole inventor for the protective agent D-methionine patents.

Notes: